Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

This study has been completed.
Sponsor:
Collaborator:
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00257478
First received: November 22, 2005
Last updated: June 6, 2012
Last verified: June 2012
  Purpose

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.


Condition Intervention Phase
Prostate Cancer
Cancer of Prostate
Prostatic Cancer
Cancer of the Prostate
Drug: YM155
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Study Completion Date: March 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed prostate cancer.
  • Prior chemotherapy regimen for prostate cancer

Exclusion Criteria:

  • History of other malignancy in the last 5 years
  • Major surgery within the past 21 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00257478

Locations
United States, Arizona
Tuscon, Arizona, United States, 85724
United States, California
Los Angeles, California, United States, 90033
United States, Idaho
Coeur d'Alene, Idaho, United States, 83814
United States, New York
Bronx, New York, United States, 10461
New York, New York, United States, 10016
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19111
United States, Texas
San Antonio, Texas, United States, 78229
Netherlands
Amsterdam, Netherlands
United Kingdom
Sutton, Surry, United Kingdom, SM2 5Pt
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma US, Inc.
Investigators
Study Director: D. Buell, MD Astellas Pharma US, Inc.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00257478     History of Changes
Other Study ID Numbers: 155-CL-007
Study First Received: November 22, 2005
Last Updated: June 6, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Astellas Pharma Inc:
Treatment Efficacy
Treatment Effectiveness
Disease Management
Treatment
Safety

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on November 25, 2014